-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
WHO backs GLP-1 treatments to tackle obesity epidemic
A range of blockbuster weight-loss and diabetes drugs could help shift the trajectory of the global obesity epidemic, which affects over one billion people worldwide, the World Health Organization said Monday.
A new generation of appetite-suppressing drugs called GLP-1 agonists -- which includes blockbuster brands Ozempic and Mounjaro -- has become massively popular in recent years.
On Monday, the United Nations health agency issued its first guidelines on how such drugs could be used as a key tool for treating obesity in adults as a chronic, relapsing disease.
More than 3.7 million people died from illnesses related to being overweight or obese in 2022, according to WHO figures -- more than top infectious killers malaria, tuberculosis and HIV combined.
The number of people living with obesity will double by 2030 unless decisive action is taken to stem the rise, the agency estimates.
"Obesity is one of the most serious public challenges of our time," WHO chief Tedros Adhanom Ghebreyesus told reporters from the agency's Geneva headquarters.
"These new medicines are a powerful clinical tool, offering hope to millions."
- Not 'a magic bullet' -
The new guidelines call for GLP-1 therapies to be used by adults, excluding pregnant women, "for the long-term treatment of obesity", which it defines as a Body Mass Index (BMI) of 30 or higher.
WHO stressed that while the efficacy of the therapies in treating obesity was "evident", it was issuing "conditional recommendations" for use since more data was needed on efficacy and safety over longer periods.
The agency also emphasised that the medication alone would not reverse the trend in obesity, which it recognised as a complex, chronic disease and a major driver of non-communicable diseases, including cardiovascular disease, type-2 diabetes and some types of cancer.
The new guidelines suggest the therapies could be coupled with "intensive behavioural interventions", promoting healthy diet and physical activity, amid indications such shifts may enhance treatment outcomes.
The WHO also insisted on the importance of "creating healthier environments through robust population-level policies to promote health and prevent obesity".
It also urged targeted screening of high-risk individuals and ensuring access to lifelong, person-centred care.
"You can't see these drugs as a magic bullet," Jeremy Farrar, WHO assistant director-general in charge of health promotion, disease prevention and care, told AFP.
"But they're clearly going to become a very important part of an integrated approach to obesity," he said.
If countries get the combination right, "the impact on bringing down levels of the people who are obese, and the impact particularly on diabetes... on cardiovascular and others, is going to be profound".
- Bending the trajectory -
Francesca Celletti, a WHO senior advisor on obesity, agreed.
"There is a possibility that we can bend this epidemiological trajectory of obesity," she told AFP.
Beyond the health impacts, the global economic cost of obesity is predicted to hit $3 trillion annually by the end of this decade, the WHO said.
"If we don't somehow shift the curve, the pressure on health systems is actually going to be untenable," Farrar warned.
The sky-high prices of GLP-1 drugs have raised concerns that they will not be made available in poorer nations where they could save the most lives.
Diabetes patients, for whom the drugs were originally developed, have also experienced shortages.
In September, the WHO added GLP-1s to its list of essential medicines in a bid to shore up access, calling for cheap generic versions to be made available for people in developing countries.
"Our greatest concern is equitable access," Tedros said.
"Without concerted action, these medicines could contribute to widening the gap between the rich and poor, both between and within countries."
T.Sanchez--AT